Management of Nonfunctioning Recurrent Pituitary Adenomas
- PMID: 31471054
- DOI: 10.1016/j.nec.2019.05.006
Management of Nonfunctioning Recurrent Pituitary Adenomas
Abstract
Pituitary adenomas are typically slow-growing benign tumors. However, 50% to 60% of tumors progress following subtotal resection and up to 30% recur after apparent complete resection. Options for treatment of recurrent pituitary adenomas include repeat surgical resection, radiation therapy, and systemic therapies. There is no consensus approach for the management of recurrent pituitary adenomas. This article reviews the natural history of recurrent adenomas and emerging biomarkers predictive of clinical behavior as well as the outcomes associated with the various treatment modalities for these challenging tumors, with an emphasis on the surgical treatment.
Keywords: KNOSP grade; Pituitary adenomas; Recurrent pituitary tumor; Transsphenoidal surgery.
Copyright © 2019 Elsevier Inc. All rights reserved.
Similar articles
-
Endoscopic endonasal transsphenoidal approach to large and giant pituitary adenomas: institutional experience and predictors of extent of resection.J Neurosurg. 2014 Jul;121(1):75-83. doi: 10.3171/2014.3.JNS131679. Epub 2014 May 2. J Neurosurg. 2014. PMID: 24785323
-
Surgical treatment of giant pituitary adenomas: strategies and results in a series of 95 consecutive patients.Neurosurgery. 2007 Jun;60(6):993-1002; discussion 1003-4. doi: 10.1227/01.NEU.0000255459.14764.BA. Neurosurgery. 2007. PMID: 17538372
-
Multimodality treatment for invasive pituitary adenomas.Postgrad Med. 2009 Mar;121(2):168-76. doi: 10.3810/pgm.2009.03.1989. Postgrad Med. 2009. PMID: 19332975 Review.
-
[RADIOSURGERY FOR PITUITARY ADENOMAS].Harefuah. 2017 Jan;156(1):45-50. Harefuah. 2017. PMID: 28530316 Review. Hebrew.
-
Surgical Outcome of Endoscopic Endonasal Surgery of Large and Giant Pituitary Adenomas: An Institutional Experience from the Middle East.World Neurosurg. 2019 Dec;132:e802-e811. doi: 10.1016/j.wneu.2019.08.004. Epub 2019 Aug 9. World Neurosurg. 2019. PMID: 31404693
Cited by
-
Clinical relevance of tumor consistency in pituitary adenoma.Hormones (Athens). 2021 Sep;20(3):463-473. doi: 10.1007/s42000-021-00302-5. Epub 2021 Jun 19. Hormones (Athens). 2021. PMID: 34148222 Review.
-
Outcome of Endoscopic Transsphenoidal Surgery for Recurrent or Residual Pituitary Adenomas and Comparison to Non-Recurrent or Residual Cohort by Propensity Score Analysis.Front Endocrinol (Lausanne). 2022 Apr 25;13:837025. doi: 10.3389/fendo.2022.837025. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 35547003 Free PMC article.
-
Predictors of progression after surgery in non-functioning pituitary macroadenomas: a Spanish multicenter study.J Endocrinol Invest. 2025 Aug 8. doi: 10.1007/s40618-025-02674-6. Online ahead of print. J Endocrinol Invest. 2025. PMID: 40779234
-
A Preoperative MRI-Based Radiomics-Clinicopathological Classifier to Predict the Recurrence of Pituitary Macroadenoma Within 5 Years.Front Neurol. 2022 Jan 5;12:780628. doi: 10.3389/fneur.2021.780628. eCollection 2021. Front Neurol. 2022. PMID: 35069413 Free PMC article.
-
Treatment of non-functioning pituitary adenoma with cabergoline: a systematic review and meta-analysis.Pituitary. 2022 Dec;25(6):810-818. doi: 10.1007/s11102-022-01257-5. Epub 2022 Jul 28. Pituitary. 2022. PMID: 35902444
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical